[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-diseases-interstitial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-diseases-interstitial":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,70,94,122,154,179,199,223,246,269,293,319,342],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100541118","phase-2-h01-in-adults-with-interstitial-lung-disease-the-solis-study-100541118",false,"NCT06325696","H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Ability of subject to understand, and the willingness to sign a written informed consent document and comply with requirements of the study\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or Female participants ages \\>18 years\n* MD diagnosis of Idiopathic Pulmonary Fibrosis or other progressive ILD as defined previously\n* DLCO\\>30% and FVC\\>45%\n* Subjects in reproductive age who are heterosexually active must use an acceptable method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, IUD, or Hormone-based contraceptive\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Active on lung transplantation list\n* On supplemental oxygen at rest\n* Evidence of an acute respiratory infection or exacerbation of pulmonary fibrosis\n* Known diagnosis of celiac disease or wheat or gluten allergies\n* Cirrhosis or active viral or non-viral hepatitis: Bilirubin, AST and ALT values higher than twice the upper range of normal, or a Child-Pugh score of 7 or more\n* Subjects with history of active Inflammatory Bowel Disease, dysphagia, achalasia, or difficulty swallowing capsules, tablets or pills\n* Subjects with significant renal impairment defined as eGFR lower than 40 ml\u002Fmin.\n* Subjects with a baseline corrected Fridericia's QT interval (QTcF) \\>450ms or baseline ECG abnormalities which, in the opinion of the study physician, are clinically significant and would place the participant at increased risk for adverse effects.\n* Subjects with ongoing alcohol or illegal drug use disorder\n* Subjects who are pregnant, lactating or attempting to conceive\n\n  * Participants able to become pregnant (have not completed menopause, had a hysterectomy and\u002For both tubes and\u002For both ovaries removed) must use effective birth control methods to try and not become pregnant while participant in this study. Methods include (a) partner vasectomy, (b) bilateral tubal ligation, (c) intrauterine devices (IUDs), (d) hormonal implants (such as Implanon), or (e) other hormonal methods (birth control pills, injections, patches, vaginal rings).\n  * Male participants able to father children with a partner able to become pregnant must agree to use effective birth control (listed above) to participate in this study.\n* Known allergy to hymecromone or any component thereof\n* Chronic therapy with medications that are known potent human UDP-glucuronosyltransferase inhibitors: canagliflozin, temazepam, tacrolimus.\n* Physician concern that participant may not adhere to the study protocol\n* Current participation in another clinical treatment trial for ILD. May participate after 12 weeks from conclusion of another treatment trial.\n* Changing dose of other ILD medications over the 3 months prior to baseline\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that place the participant at increased risk for adverse effects, as determined by the study physician.","ALL","18 Years","100 Years",{"count":20,"type":21},37,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nInterstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years.\n\nObjective:\n\nTo test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis.\n\nEligibility:\n\nPeople aged 18 years and older with interstitial lung disease or lung fibrosis.\n\nDesign:\n\nParticipants will have at least 7 clinic visits over 5 months.\n\nParticipants will have screening and baseline visits. They will have blood tests and tests of their heart function. They will give a sputum sample. Other tests will include:\n\nSpirometry: Participants will breathe in and out through a mouthpiece to measure how much air they can hold in their lungs and how hard they can breathe.\n\nDiffusion capacity of lungs for carbon monoxide: Participants will breathe in a gas that contains a small amount of carbon monoxide. Then they will breathe through a mouthpiece. This test measures how well oxygen moves from the air into the blood.\n\nResting energy expenditure. Participants will lie still for 30 minutes with a clear dome over their head. This test measures the calories their body burns at rest.\n\n6-minute walk test. Participants will walk at their normal pace for 6 minutes. Their vital signs and blood oxygen levels will be checked.\n\nHymecromone is a tablet taken by mouth. Participants will take 2 tablets every morning and 2 tablets every night for 12 weeks. Tests will be repeated at study visits.",[27,28,29],"Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis","Lung Diseases, Interstitial",[31,32,33,34],"Pulmonary Fibrosis","Lung disease","Hyaluronan","Drug","RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2025-05-05",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"National Institute of Environmental Health Sciences (NIEHS)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":47},"100502217","connective-tissue-disease-associated-interstitial-lung-diseases-ctd-ild-epidemiology-non-interventional-study-nis-100502217","NCT05819385","Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)","Ambispective, Non-Interventional Study to Evaluate the Epidemiology of Interstitial Lung Diseases (ILDs) Associated to Rheumatic Diseases (Rheumatoid Arthritis, Connective Tissue Diseases, Spondylarthritis and Sarcoidosis) and the Progression Risk Factors in the Mexican Population","Inclusion Criteria:\n\nFor newly data collection:\n\n* Male and female Patients.\n* Patients over 18 years old.\n* Patient who gives his\u002Fher signed informed consent to be able to use information about their condition.\n* Patient who has the diagnosis of: rheumatoid arthritis, connective tissue disease (CTD) (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) Spondyloarthritis (SpA) or sarcoidosis, (accordingly with the updated clinical criteria for each pathology).\n\nPatient with any interstitial lung diseases (ILD) diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).\n\nFor existing data collection:\n\n* Medical Records from patients with whom contact was permanently lost for any reason since 2012 till the study start date.\n* Medical Records from male and female Patients.\n* Medical Records from patients over 18 years old.\n* Medical Records of patients that have at least: patient initials, date of birth, gender, date of diagnosis, full diagnosis of:\n\n  * Patient who has the diagnosis of: rheumatoid arthritis, CTD (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; Systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) SpA or Sarcoidosis, (accordingly with the updated clinical criteria for each pathology).\n  * Patient with any ILD diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).\n\nExclusion Criteria:\n\n* Patient with a biopsy definition of usual interstitial pneumonitis, related to any other non-CTD.\n* Patient with post-chemotherapy or post-radiotherapy pneumonitis.\n* Medical Records of patients without full diagnostic of ILD (clinically and by biopsy or high-resolution computed tomography).",{"count":56,"type":21},312,"OBSERVATIONAL","This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.",[29],"2026-05-04",{"date":62,"type":39},"2026-05-07",{"date":64,"type":39},"2025-06-18",{"date":66,"type":21},"2027-12-01",{"name":68,"class":69},"Boehringer Ingelheim","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":47},"100494758","nivats-versus-igavats-a-pilot-trial-addressing-biopsy-quality-in-undetermined-interstitial-lung-diseases-100494758","NCT05722340","NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases","Video-assisted Thoracic Surgery for Lung Biopsy Using Non-intubated (NIVATS) Versus Intubated General Anaesthesia (IGAVATS): a Randomized, Controlled, Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases","NIVATS-2","Inclusion Criteria:\n\n* Patient with purported interstitial lung disease\n* Patient requiring a surgical lung biopsy to reinforce diagnosis according to current recommendations and validated by a multidisciplinary assessment\n* Minimum age: 18 years\n\nExclusion Criteria:\n\n* Contra-indication for surgery\n* Uncontrolled oesophageal gastric reflux despite optimal treatment\n* Thoracic deformation (For example, pectus excavatum\u002Fcarinatum or major scoliosis)\n* Risk of pleural adhesion (For example, patient who has already undergone thoracic surgery)\n* History of abnormal bleeding\n* Predictable risk of difficult intubation\n* Body mass index (BMI) \\> 30\n* Severe cardiovascular comorbidity (For example, instable ischemic cardiomyopathy)\n* Unable to comply with all trial procedures\u002Fvisits (For example, language barriers, upcoming move of household to another region, unwillingness to schedule the required followup visits.)\n* Protected populations according to the French Public Health Code Articles L1121-5,6,8 (For example, pregnant, parturient or lactating women, prisoners, adults under guardianship or otherwise unable to consent.)\n* Potential interference from another study (The patient is participating in another interventional study, or has done so in the past month, or is affected by an exclusion period stipulated by a previous study.)\n* Non-beneficiary of the French single-payer national medical insurance system\n* Lack of signed informed consent",{"count":79,"type":21},24,[81],"NA","The main objective of this study is to compare two independent groups of patients requiring lung biopsy for undetermined interstitial lung disease (ILD) in terms of diagnostic confidence as determined by histologists.",[29],"2026-03-27",{"date":86,"type":39},"2026-04-02",{"date":88,"type":39},"2023-05-24",{"date":90,"type":21},"2026-11-24",{"name":92,"class":93},"University Hospital, Montpellier","OTHER",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100629363","phase-2-study-of-tx000045-in-participants-with-pulmonary-hypertension-due-to-interstitial-lung-disease-100629363","NCT07473700","Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease","An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease","Inclusion Criteria:\n\n* Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater than or equal to (\\>=) 10 percent (%) lung parenchyma with fibrosis) consistent with idiopathic interstitial pneumonia, ILD in association with connective tissue disease, occupational ILD, or chronic hypersensitivity pneumonitis. Chest CTs will be centrally read for eligibility\n* 40% predicted less than or equal to (\\\u003C=) forced vital capacity (FVC) \\\u003C= 80% predicted at screening\n* At least ONE of the following is required to undergo the first screening visit: Documented diagnostic right heart catheterization (RHC) within 18 months of screening with mean pulmonary arterial pressure (mPAP) \\>= 25 millimeters of mercury (mm Hg), pulmonary capillary wedge pressure (PCWP) \\\u003C=15 mm Hg, and pulmonary vascular resistance (PVR) \\>=4 Wood units; Documented echocardiogram (ECHO) within 18 months of screening with right ventricular (RV) (or pulmonary artery) systolic pressure \\>46 mm Hg or tricuspid annular plane systolic excursion (TAPSE)\u002F systolic pulmonary artery pressure (SPAP) \\\u003C=0.38 and absence of clinically significant left ventricular dysfunction as assessed by the investigator\n\nExclusion Criteria:\n\n* Participants have a confirmed or suspected diagnosis of pulmonary hypertension in World Health Organization (WHO) Group 1, WHO Group 2, WHO Group 4, or WHO Group 5\n* Participants have received phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators, intravenous (IV) or subcutaneous (SC) prostacyclin analogues within 30 days before the first screening visit, or sotatercept within 180 days before the first screening visit\n* Participants have any type of pulmonary and cardiovascular comorbidities as defined n protocol\n* Participants who are taking disease-modifying therapy for the underlying interstitial lung disease (ILD) (anti-fibrotics, immunosuppressives, and anti-inflammatory medications) who are not on stable doses for \\>30 days before the first screening visit or have initiated new ILD-directed therapies within 90 days before the first screening visit","80 Years",{"count":103,"type":21},25,[24],"The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.",[107,29],"Hypertension, Pulmonary",[109,110],"Interstitial lung disease","pulmonary vascular resistance","NOT_YET_RECRUITING","2026-03-10",{"date":114,"type":39},"2026-03-16",{"date":116,"type":21},"2026-03-30",{"date":118,"type":21},"2027-12-11",{"name":120,"class":69},"Tectonic Operating Company, Inc.",6,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100560072","phase-3-a-study-of-the-efficacy-and-safety-of-belimumab-in-adults-with-interstitial-lung-disease-associated-with-connective-tissue-disease-100560072","NCT06572384","A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)","BEconneCTD-ILD","Inclusion criteria:\n\n* Participants with persistent\u002Fworsening active inflammatory disease who have failed to achieve their treatment goal, i. e., those who have experience lack of expected treatment benefit (clinically meaningful improvement in FVC), fail to demonstrate sustained lung function stability or continue to experience worsening of ILD despite initiation of standard therapy or failed to tolerate standard therapy.\n* Documented diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM; including polymyositis, dermatomyositis, anti-synthetase syndrome), Sjogren's syndrome (pSS), or mixed connective tissue disease (MCTD) in accordance with internationally recognized classification criteria\n* Diagnosis of inflammatory and\u002For fibrotic ILD on High Resolution Computed Tomography (HRCT) with a total disease extent of greater than or equal to (≥) 10% of the whole lung\n* Evidence of persistent active\u002Fworsening ILD\n* Must be currently receiving stable standard therapy to manage ILD and\u002For underlying CTD, or to have failed or failed to tolerate standard therapy.\n* Participant is capable and willing to self-administer the study medication or has a caregiver who is capable and willing to administer the study medication throughout the study\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:\n\n  * Is a woman of nonchildbearing potential (WONCBP) OR\n  * Is a Woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\\\u003C)1%\n* Capable of giving signed informed consent\n\nExclusion Criteria:\n\n* Diagnosis of ILD other than CTD-ILD.\n* Primary diagnosis of Systemic Sclerosis (SSc).\n* Participants with rapidly progressive disease (absolute drop of 10% or more of FVC between screening and baseline visit and\u002For recent pulmonary hospitalization).\n* FVC ≤ 45% of predicted, or a Diffusing Capacity of the lung for Carbon Monoxide (DLco) (corrected for hemoglobin) ≤ 40% of predicted at screening as confirmed by central reader\n* History or presence of diffuse alveolar hemorrhage (DAH) or other confounding pulmonary disease, signs, or symptoms\n* Pulmonary arterial hypertension requiring therapy, as determined by the investigator at, or prior to first day of dosing (Day 1)\n* Dependence on continuous oxygen supplementation\n* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data\n* Obstructive pulmonary disease (pre-bronchodilator Forced Expiratory Volume (FEV1) \u002FFVC \\\u003C0.7) as confirmed by central reader\n* Significant emphysema on screening or historical HRCT (extent of emphysema exceeds extent of ILD) as confirmed by central reader\n* Confirmed Progressive multifocal leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms\n* Participants with patient health questionnaire (PHQ-9) score ≥10, that in the opinion of a mental healthcare professional pose a serious suicide risk, have or any history of suicidal behavior in the last 6 months and\u002For any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk.\n* Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years\n* Breast cancer within the past 10 years\n* Major surgery (including joint surgery) within 3 months prior to screening or planned during the duration of the study\n* An active infection, or a history of infections",{"count":131,"type":21},440,[133],"PHASE3","Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and\u002For improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.",[29],[109,137,138,139,140,29,141,142,143],"Belimumab","Connective Tissue Disease","Autoimmune disease","Lung Diseases","Safety","Efficacy","Monoclonal antibody","2026-03-02",{"date":146,"type":39},"2026-03-03",{"date":148,"type":39},"2024-09-11",{"date":150,"type":21},"2028-12-13",{"name":152,"class":69},"GlaxoSmithKline",131,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":47},"100621620","phase-1-nebulized-human-amniotic-fluid-in-patients-with-interstitial-lung-disease-100621620","NCT07372989","Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease","A Phase 1, Study of Nebulized Matrix - Allogeneic Human Amniotic Fluid (HAF) In Patients With Interstitial Lung Disease: AIRMID Trial","HAF ILD","Inclusion Criteria:\n\nIn order to participate in this study, a patient MUST:\n\n* Provide written informed consent.\n* Subjects age \\> 40 and \\\u003C 90 years at the time of signing the Informed Consent Form.\n* Have a clinical diagnosis of ILD prior to screening in accordance with the guidelines of the American Thoracic Society\u002FEuropean Respiratory Society.\n* FVC ≥ 45% predicted and DLCO ≥30% (corrected for hemoglobin but not alveolar volume).\n* Resting SpO₂ ≥ 92% on ≤ 3 L\u002Fmin O₂.\n* RVSP \\\u003C 50 mmHg, as documented by Doppler echo or right heart catheterization.\n* Female subjects must be surgically sterile or post-menopausal (\\>1 year).\n\nExclusion Criteria:\n\nIn order to participate in this study, a patient MUST NOT:\n\n* CT and\u002For surgical lung biopsy results inconsistent with the diagnosis of IPF.\n* Inability to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform PFTs or CT, undergo blood draws, read and respond to questionnaires.)\n* Currently receiving (or received within four weeks of screening) any medication, treatment, or experimental agents for the treatment of ILD, except for patients receiving non-drug therapies will include oxygen saturation therapy (oxygen supplementation) and pulmonary rehabilitation.\n* Active listing (or expected future listing) for transplant of any organ.\n* Clinically important abnormal screening laboratory values, including but not limited to: hemoglobin \\\u003C8 g\u002Fdl, white blood cell count \\\u003C3000\u002Fmm3, platelets \\\u003C80,000\u002Fmm3, INR \\> 1.5, aspartate transaminase, alanine transaminase, or alkaline phosphatase \\> 2 times upper limit of normal, total bilirubin \\> 1.5 mg\u002Fdl.\n* Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study. Including, but not limited to: HIV, advanced liver or renal failure, class III\u002FIV congestive heart failure, myocardial infarction, unstable angina, or cardiac revascularization within the last six months, or severe obstructive ventilatory defect.\n* Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.\n* Be an organ transplant recipient.\n* Have a clinical history of malignancy within 2.5 years (i.e., patients with prior malignancy must be disease free for 2.5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.\n* Have a non-pulmonary condition that limits lifespan to \\\u003C 1 year.\n* Have a history of drug or alcohol abuse within the past 24 months.\n* Be serum positive for HIV, hepatitis BsAg or Viremic hepatitis C.\n* Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\n* Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.\n* Female subjects must have an FSH \\\u003C 25.8 IU\u002FL\n* Subject with hypersensitivity to dimethyl sulfoxide (DMSO)\n* Saturated oxygen (SpO2 of \\\u003C 93% (room air \\[sea level\\] at rest). SpO2 of \\\u003C 88% (room air \\[\\>5,000 feet above sea level (1524 meters) at rest).",{"count":163,"type":21},50,[165],"PHASE1","This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD). ILDs are progressive fibrotic disorders characterized by aberrant wound-healing responses, chronic inflammation, and dysregulated fibroblast activation, ultimately leading to impaired gas exchange and respiratory failure. Current treatments, such as antifibrotic agents (pirfenidone and nintedanib), slow disease progression but do not reverse existing fibrosis or restore lung function. This pilot study will generate critical safety and preliminary efficacy data to inform future larger-scale trials and optimize dosing strategies for nebulized HAF-based therapeutics in ILD.",[29],[169],"Interstitial Lung Disease (ILD)","2026-01-27",{"date":172,"type":39},"2026-01-29",{"date":174,"type":21},"2026-02",{"date":176,"type":21},"2028-10-01",{"name":178,"class":93},"Maule Stem Cell Research Institute, Inc.",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":47},"100416830","database-for-interstitial-lung-disease-100416830","NCT04707781","Database for Interstitial Lung Disease","Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* patients with a known systemic disease bearing a risk for ILD\n* signed informed consent (for prospective part)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)",{"count":187,"type":21},412,"The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.",[29],"2026-01-13",{"date":192,"type":39},"2026-01-15",{"date":194,"type":39},"2021-05-01",{"date":196,"type":21},"2029-01-31",{"name":198,"class":93},"Medical University of Graz",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":47},"100504917","cough-capture-as-a-portal-into-the-lung-100504917","NCT05854563","Cough Capture as a Portal Into the Lung","Genetics of Lung Disease (Exhaled Breath DNA Methylation in Lung Carcinogenesis)","CC1","Inclusion Criteria:\n\n* Age: minimum age of 21 years\n* Gender: Male and Female adults\n* Ethnicity: All ethnic groups and races\n* Subjects undergoing bronchoscopy for diagnostic purposes or therapy\n* Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures\n* Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and\u002For in-hospital with exacerbation\n\nExclusion Criteria:\n\n* Bleeding diathesis or known coagulopathy precluding clinically indicated biopsy (e.g., INR\\>1.3, PTTr\\>1.3), thrombocytopenia \\\u003C50,000, uremia with serum creatinine \\>3.0\n* Unstable angina\n* Recent myocardial infarction (within 3 months),\n* Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP\\>75 mmHg)","21 Years",{"count":209,"type":21},2000,"The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection\u002Frisk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP\u002FSFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications.\n\nThe investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL\u002Fbronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg\u002FMaslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity\u002Fsaliva, in the Sidoli\u002Fproteomics core.\n\nThe investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and\u002For early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.",[140,212,213,29,214],"Lung Cancer","Lung Diseases, Obstructive","Lung Inflammation","2026-01-12",{"date":190,"type":39},{"date":218,"type":39},"2023-03-28",{"date":220,"type":21},"2027-06",{"name":222,"class":93},"Albert Einstein College of Medicine",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":47},"100077097","dorothy-p-and-richard-p-simmons-center-for-ild-research-registry-100077097","NCT00258583","Dorothy P. and Richard P. Simmons Center for ILD Research Registry","Dorothy P. and Richard P Simmons Center for Interstitial Lung Disease Research Registry","ILDRR","Inclusion Criteria:\n\n* Adult patients who are seeking treatment at the UPMC Simmons Center for Interstitial Lung Disease\n* 18 years of age or older\n\nExclusion Criteria:\n\n* N\u002FA",{"count":232,"type":21},5000,"The purpose of this study is to place past, current, and future medical record information into the UPMC Simmons Center for Interstitial Lung Disease Research Registry.",[29],[236],"\"Lung[A04.400]\"","2025-10-28",{"date":239,"type":39},"2025-10-29",{"date":241,"type":4},"2003-10",{"date":243,"type":21},"2035-07",{"name":245,"class":93},"University of Pittsburgh",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":47},"100328870","comparison-of-pr-efficiency-in-home-based-with-hospital-based-pr-in-bronchiectasis-100328870","NCT03561818","Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis","Comparison of Pulmonary Rehabilitation Efficiency in Home-based With Hospital-based Pulmonary Rehabilitation in Bronchiectasis","Inclusion Criteria:\n\n* Between the ages of 18-70\n* Patients signing informed consent form\n* Bronchiectasis patients in the stable phase who were diagnosed with High-resolution computed tomography (HRCT).\n\nExclusion Criteria:\n\n* Decompensated heart failure, uncontrolled hypertension (Systolic Blood Pressure\\> 200, Diastolic Blood Pressure\\> 110),\n* Additional diseases that may prevent exercise,\n* To be regularly exercising regularly","75 Years",{"count":163,"type":21},[81],"The investigators aimed to compare the home-based Pulmonary Rehabilitation with the hospital-based pulmonary rehabilitation in terms of pulmonary rehabilitation efficiency in patient with bronchiectasis.",[258,259,140,29],"Bronchiectasis","Pulmonary Rehabilitation","2025-04-29",{"date":262,"type":39},"2025-05-01",{"date":264,"type":39},"2018-06-19",{"date":266,"type":21},"2026-12-30",{"name":268,"class":93},"Istanbul Medipol University Hospital",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100525476","a-randomised-clinical-trial-of-a-digital-self-management-package-for-people-with-interstitial-lung-disease-100525476","NCT06122233","A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease","Inclusion Criteria:\n\n* Diagnosis of fibrotic ILD\n* In possession of a smartphone\u002Ftablet and an email address\n* Able to understand written and spoken English\n* Adequate digital literacy to complete requirements of trial\n* On stable ILD treatment for 30 days prior to enrolment\n\nExclusion Criteria:\n\n* Not in possession of a smartphone\u002Ftablet\n* Insufficient digital literacy to complete requirements of trial\n* Unable to communicate in written\u002Fspoken English\n* Not on stable ILD treatment for 30 days prior to enrolment\n* Acute exacerbation within 30 days prior to enrolment\n* Participating in pulmonary rehab at enrolment or during 12-week intervention period\n* Unable to provide informed consent",{"count":276,"type":21},400,[81],"The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease (ILD). The main question it aims to answer is:\n\n• Does REBUILD-SM improve health-related quality of life, symptoms, anxiety, self-efficacy and physical activity for people with ILD?\n\nParticipants in the intervention group will work through the self-management package with support from a healthcare professional via phone or Zoom. They will also enter deidentified health data into the RE-BUILD smartphone app to track their progress over time. Participants in the control group will use a reduced functionality version of the smartphone app only.\n\nResearchers will compare both groups to see if there is any difference in health-related quality of life, symptoms, anxiety, self-efficacy and level of physical activity.",[29,31],[281,282],"Self-Management","Chronic diseases","2025-04-01",{"date":285,"type":39},"2025-04-04",{"date":287,"type":39},"2024-06-03",{"date":289,"type":21},"2027-08",{"name":291,"class":93},"University of Sydney",4,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":318},"100549952","phase-2-efficacy-and-safety-of-olokizumab-in-patients-with-progressive-fibrosing-interstitial-lung-diseases-100549952","NCT06440746","Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases","A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase 2\u002F3 Study of Efficacy and Safety of Olokizumab in Subjects With Progressive Fibrosing Interstitial Lung Diseases","Inclusion Criteria:\n\n1. The patient has signed the Informed Consent Form\n2. Progressive fibrosing ILD confirmed by high-resolution computed tomography (HRCT) documented evidence of \\>10% lung tissue affected at Screening:\n\n   A. Patients with an usual interstitial pneumonia (UIP) -like radiological pattern described in the 2022 American Thoracic Society\u002FEuropean Respiratory Society\u002FJapanese Respiratory Society\u002FLatin American Thoracic Association guidelines for the management Idiopathic pulmonary fibrosis (IPF) that do not have an identified primary condition\n\n   В. Patients with progressive interstitial pneumonia with autoimmune features (IPAF) as defined in the American Thoracic Society\u002FEuropean Respiratory Society Statement, 2015\n\n   С. Patients with progressive lung fibrosis associated with different disorders (c) such as systemic connective tissue diseases, chronic fibrosin hypersensitivity pneumonitis (HP), idiopathic non-specific interstitial pneumonia (iNSIP) or sarcoidosis.\n\n   Disease progression will be established based on a combination of criterion (I)(a) and criterion (II) or criterion (III)(b)\n\n   I. Clinically significant decrease in FVC% predicted defined as absolute decrease of ≥ 5% within 12 months prior to screening or an absolute decrease DLCO (corrected for hemoglobin) of ≥10% predicted within 12 months prior to screening.\n\n   II. Worsening respiratory symptoms without an alternative explanation within 12 months prior to screening.\n\n   III. Increased area affected with fibrosis on chest HRCT (b) (according to the 2022 American Thoracic Society\u002FEuropean Respiratory Society\u002FJapanese Respiratory Society\u002FLatin American Thoracic Association guidelines) within 24 months prior to screening.\n   1. To assess this criterion (I), patient's pulmonary function test (PFT) results obtained within 12 months prior to screening must available. If data from multiple PFTs are available, the earliest results must be used for assessment.\n   2. Patients' results of at least one chest HRCT investigation performed no earlier than 24 months before randomization must be available for review. If results of multiple HRCT examinations are available, patient eligibility must be based on the earliest results.\n   3. stable course of the main disease not requiring a change in maintenance treatment.\n3. ILD duration of no more than 8 years from the onset of respiratory symptoms by the date screening begins.\n4. Elevated acute phase reactants at screening not related to other causes:\n\n   C-reactive protein level ≥6 mg\u002Fl or Erythrocyte Sedimentation Rate (ESR) ≥28 millimeters per hour (mm\u002Fhour).\n5. FVC ≥ 45% and ≤ 80% predicted at screening.\n\nNon-Inclusion Criteria:\n\n1. Hemoglobin-corrected DLCO \\\u003C 30% predicted at screening.\n2. Significant airway obstruction at screening defined as a Forced expiratory volume in 1 second (FEV1) \u002F FVC ratio of \\\u003C70 %.\n3. Use of interleukin-6(IL-6 )inhibitors or IL-6 receptor inhibitors except for CoronaVirus Disease2019 (COVID-19) treatment. If those medications are used to treat COVID-19, the last administration of IL-6 inhibitors or IL-6 receptor inhibitors must have occurred at least 6 months prior to screening.\n4. Administration of rituximab within less than 12 months prior to screening.\n5. Treatment with systemic glucocorticosteroids (GCS) at \\>10 mg\u002Fday calculated for prednisolone; or a change in the dose of GCS within 4 weeks before\u002Fduring the screening period; or planned dose changes during the trial.\n6. A history of bone marrow transplantation, total lymphoid tissue irradiation, or administration of ablative ultra-high doses of cyclophosphamide.\n7. Initiation of mycophenolate mofetil or antifibrotic agents (for patients receiving mycophenolate mofetil and\u002For antifibrotics at study entry) less than 12 months prior to screening.\n\n   • If a patient has been taking antifibrotic drugs for \\\u003C12 months and ≥6 months, and the spirometry\u002FDiffusion Capacity Of The Lungs For Carbon Monoxide (DLCO) used to assess progression was performed within ±2 weeks of actually starting antifibrotic drugs, the patient may be included in the study\n8. Discontinuation of previously prescribed antifibrotic agents within 6 months prior to screening (for patients not receiving antifibrotic drugs at study entry).\n9. Participation in any other clinical trial less than 30 days prior to the baseline assessment or less than 5 half-lives of the medication examined in another clinical trial, whichever is longer.\n10. Laboratory abnormalities as follows:\n\n    * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase(AST) ≥ 1.5×Upper Limit Normal (ULN)\n    * Platelet count \\\u003C100×10\\^9\u002Flitre (l) (\\\u003C100000\u002Fcubic millimetre (mm\\^3)\n    * Leukocyte count \\\u003C3.5×10\\^9\u002Fl\n    * Absolute neutrophil count \\\u003C2000×10\\^6\u002Fl (\\\u003C2000\u002Fmm\\^3).\n11. Concurrent malignancy or a history of malignancy within the last 5 years.\n12. Any acute infection at screening or exacerbation of a chronic infection, any infection requiring oral antibiotics or antivirals within 4 weeks prior to screening, injection of antimicrobial agents within 6 weeks before randomization, severe or recurrent infections requiring hospital admission within 6 months before randomization.\n13. Patients with evidence of disseminated herpes zoster infection, herpes zoster with encephalitis, meningitis, or other forms of herpes zoster infection that do not resolve without treatment and occurred within 6 months prior to screening.\n14. Evidence of any other chronic infection (including sepsis, invasive fungal infection, histoplasmosis, osteomyelitis) which, in the opinion of the Investigator, may increase the risk of infectious complications during the trial.\n15. Patients with diverticulitis or other symptomatic gastrointestinal diseases that may lead to perforation, including such history (for example, diverticulitis, gastrointestinal perforation, ulcerative colitis).\n16. Women of child-bearing potential or men whose partners are women of child-bearing potential who do not want to use highly effective methods of contraception during the trial and for at least 3 months after the last administration of the investigational product.\n17. Known hypersensitivity to OKZ or any other component of the product or placebo.\n18. History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.\n19. Other protocol-defined non-inclusion criteria apply.",{"count":301,"type":21},138,[24,133],"The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).",[29],[306,307,308],"Progressive Fibrosing Interstitial Lung Diseases","Olokizumab","Forced vital capacity","2024-11-15",{"date":311,"type":39},"2024-11-19",{"date":313,"type":39},"2023-08-23",{"date":315,"type":21},"2028-12-25",{"name":317,"class":69},"R-Pharm International, LLC",33,{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":47},"100424454","a-single-cell-approach-to-identify-biomarkers-of-efficacy-and-toxicity-for-ici-in-nsclc-100424454","NCT04807114","A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC","A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for Immune Checkpoint Blockade in Non-small Cell Lung Cancer","Inclusion criteria:\n\n* Adult M\u002FF\u002FX (\\>= 18 years)\n* Histologically and clinically confirmed diagnosis of non-small cell lung cancer (according to IASLC Staging Handbook in Thoracic Oncology v7)\n* Patients receiving first-line treatment per guidelines\n* Not included in other clinical trials\n* Signed informed consent form\n\nExclusion criteria:\n\n• Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and\u002For bio-informatician, specialized in single-cell analysis.","120 Years",{"count":328,"type":21},70,"The main goal of this prospective non-interventional exploratory study is to characterize the tumor micro-environment of advanced NSCLC in single-cell resolution, prior to immune checkpoint blockade exposure, and correlate the findings to clinical outcome. This approach will allow to generate new hypotheses regarding mechanism of action of ICI and (primary) resistance mechanisms. The long-term goal is that these novel mechanistic insights will be translated to a clinical setting to develop better biomarkers of ICI efficacy. Importantly, since the investigators will also sequentially profile the immune composition of peripheral blood, this research offers an opportunity to develop circulating (non-invasive) biomarkers.\n\nA second aim is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from these ICI-treated cancer patients if they would develop ICI-pneumonitis. These mechanistic insights can directly lead to putative diagnostic biomarkers and therpeutic targets. Since single-cell profiling of blood samples will also be performed, circulating biomarkers of ICI toxicity can also be identified, making non-invasive diagnosis feasible.",[29,331,332],"NSCLC","Immunotherapy","2024-06-28",{"date":335,"type":39},"2024-07-01",{"date":337,"type":39},"2020-02-01",{"date":339,"type":21},"2025-01-31",{"name":341,"class":93},"Universitaire Ziekenhuizen KU Leuven",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":350,"targetDuration":352,"studyType":57,"phases":4,"briefSummary":353,"conditions":354,"keywords":359,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":370},"100274490","european-management-platform-for-childhood-interstitial-lung-diseases---child-eu-register-and-biobank-100274490","NCT02852928","European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank","Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases \u002F chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease","chILD-EU","Inclusion Criteria:\n\n* all children with suspected or\n* verified diagnosis of ILD or\n* masquerading as ILD and\n* those with rare localized parenchymal lung diseases\n\nExclusion Criteria:\n\n* other indication as inclusion criteria",{"count":351,"type":21},1000,"10 Years","Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes",[29,355,356,31,357,358],"Pulmonary Alveolar Proteinosis","Pulmonary Eosinophilia","Respiratory Distress Syndrome, Newborn","Child",[360],"ILD; chILD","2022-09-18",{"date":363,"type":39},"2022-09-21",{"date":365,"type":39},"2013-12",{"date":367,"type":21},"2029-12",{"name":369,"class":93},"Matthias Griese",3]